We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-6 of 6

U.S. extends commitment to fund cooperative energy commercialization program for partnering Israeli and U.S. companies
  • Sullivan & Worcester LLP
  • USA, Israel
  • January 21 2015

On December 19, 2014, President Obama signed into law S. 2673, which extends Congressional authorization for the BIRD Foundation’s Energy Program


Israeli Parliament Committee amends disclosure requirements of top executives' compensation terms
  • Sullivan & Worcester LLP
  • USA, Israel
  • September 24 2014

Until now, many Israeli companies listed on U.S. stock exchanges have enjoyed minimal disclosure requirements regarding the compensation paid, on an


The Physician Payment Sunshine Act is now a reality for physicians, pharmaceutical companies and medical device manufacturers
  • Sullivan & Worcester LLP
  • USA
  • September 25 2013

Under the Physician Payment Sunshine Act (the "Sunshine Act"), which is part of the 2010 healthcare reform legislation (also known as Obama Care)


Will foreign private issuers be subject to a stricter disclosure regime?
  • Sullivan & Worcester LLP
  • USA
  • April 18 2012

In a recent speech, Meredith Cross, director of the SEC’s Division of Corporation Finance, observed that the SEC’s staff has noticed a fundamental change in the demographics of foreign private issuers registered in the United States that may indicate the need for a change in their U.S. reporting regime.


Oded Har-Even
  • Sullivan & Worcester LLP